Questions with no answer at all. Not questions with no accepted answer — those are elsewhere.
What I am working with: 8 units · 8 mg/mL. This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory. What I…
Stated plainly: retatrutide · 5 mg/mL. I have worked this out and I would like someone to find the error, because I suspect there is one. My working so far, for the…
Setup, so nobody has to ask: 0.9% sodium chloride · fourteen days. This is a procedural question rather than a theoretical one, and I would like the procedure rather…
Details up front: a TFA mobile phase · dulaglutide · a C4 column. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have…
What I have: STEP 3 · semaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Details up front: cagrilintide · 0.9% sodium chloride. I would like to understand the steps well enough to explain them to someone else. I have access to a…
The case in front of me: 40 mg · 2 mL · 0.9% sodium chloride. I want the working, not the result — I need to be able to redo it with different numbers. I care about…
The specifics, since they change the answer: FLOW · semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious…
The specifics, since they change the answer: creatinine · cystatin C · semaglutide. I suspect the honest answer is that it depends, in which case I would like to know…
What I am working with: Medutest · Janoshik · tirzepatide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have…
What I have: survodutide · twenty-eight days. I have done this once and I suspect I got away with it rather than got it right. For context: I keep records of every…
Details up front: CPC · Sangon Biotech (Shanghai). I would like the axes of comparison first and the recommendation second. I have tried the first option and it…
Setup, so nobody has to ask: AST · semaglutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping…
What I am working with: dimerisation · a GLP-1 receptor agonist · 2–8 °C. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make…
I have both a purity figure and a content figure, which is why the discrepancy is visible. This is presented as though it settles something, and I am not convinced it…
The case in front of me: SGN · Nantong · Australia. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me…
The case in front of me: KP · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
For reference: tirzepatide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for price,…
For reference: liraglutide · 0.5 mg. I would like the arithmetic checked rather than the conclusion asserted. I have deliberately not used an online calculator…
Stated plainly: dulaglutide · two weeks · 2–8 °C. I am trying to build something sustainable rather than something thorough that I will abandon. I have already…
Setup, so nobody has to ask: SURMOUNT-4 · tirzepatide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources…
The case in front of me: batch certificate · WXT. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me…
Conditions: 97.9% · method section. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
The specifics, since they change the answer: 4 mg · 2.5 mL · phosphate-buffered diluent. I would like the arithmetic checked rather than the conclusion asserted. I…